News

Mar. 23. 2020

Notice of Change in Representative Directors

Mar. 06. 2020

Sawai Launches Tadalafil Tablets

Feb. 20. 2020

Sawai Receives Approval for Tadalafil Tablets

Feb. 17. 2020

Sawai Receives Approvals for 15 Generic Drugs with 31 Strengths

Feb. 14. 2020

Sawai Reports Third Quarter FY2019 Financial Results

Jan. 30. 2020

Upsher-Smith Launches Clonidine Hydrochloride Extended-Release Tablets

Jan. 16. 2020

Upsher-Smith Launches Haloperidol Tablets

Jan. 14. 2020

Upsher-Smith Launches Fluvoxamine Maleate Tablets

Dec. 12. 2019

Sawai Launches Two Generic Drugs with Five Strengths

Nov. 08. 2019

Sawai Reports First Half of FY2019 Financial Results

Oct. 08. 2019

Upsher-Smith Launches Tosymra^™ (sumatriptan) Nasal Spray for the Acute Treatment of Migraine in Adults

Sep. 06. 2019

Upsher-Smith Launches Morphine Sulfate Tablets

Aug. 28. 2019

MHLW Approves Additional Indications for CANDESARTAN Tablets and OD Tablets2

Aug. 15. 2019

Sawai Receives Approvals for Two Generic Drugs with Five Strengths

Aug. 06. 2019

Sawai Reports First Quarter FY2019 Financial Results

Jul. 23. 2019

Sawai Selected for FTSE4Good and FTSE Blossom Japan Indexes

Jul. 22. 2019

Upsher-Smith Laboratories Completes Acquisition of Two Treatments for Acute Migraine in Adults

Jun. 21. 2019

Osteoporosis drug "Minodronic Acid Tablets 50 mg [SAWAI]" wins "World Star Awards" in a prestigious packaging contest.

Jun. 18. 2019

MHLW Approves Additional Indications for METHOTREXATE Capsules

Jun. 14. 2019

Upsher-Smith Laboratories Enters Into Agreement to Acquire Tosymra^™ and Zembrace^® Symtouch^®

Jun. 13. 2019

Sawai Launches Three Generic Drugs with Seven Strengths

Jun. 05. 2019

MHLW Approves Additional Indication for LINEZOLID Injection and Tablets

May. 14. 2019

Sawai Reports FY2018 Financial Results

Mar. 28. 2019

Upsher-Smith Launches Generic Version of Prozac^® (Fluoxetine) Tablets